98 related articles for article (PubMed ID: 19685531)
1. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma.
Javeri H; Xiao L; Rohren E; Lee JH; Liao Z; Hofstetter W; Maru D; Bhutani MS; Swisher SG; Macapinlac H; Wang X; Ajani JA
Cancer; 2009 Nov; 115(22):5184-92. PubMed ID: 19685531
[TBL] [Abstract][Full Text] [Related]
2. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma.
Hong D; Lunagomez S; Kim EE; Lee JH; Bresalier RS; Swisher SG; Wu TT; Morris J; Liao Z; Komaki R; Ajani JA
Cancer; 2005 Oct; 104(8):1620-6. PubMed ID: 16118804
[TBL] [Abstract][Full Text] [Related]
3. Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation.
Javeri H; Xiao L; Rohren E; Komaki R; Hofstetter W; Lee JH; Maru D; Bhutani MS; Swisher SG; Wang X; Ajani JA
Cancer; 2009 Feb; 115(3):624-30. PubMed ID: 19130466
[TBL] [Abstract][Full Text] [Related]
4. Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography.
Patnana SV; Murthy SB; Xiao L; Rohren E; Hofstetter WL; Swisher SG; Liao Z; Lee JH; Bhutani MS; Macapinlac HA; Wang X; Ajani JA
Cancer; 2010 Oct; 116(19):4487-94. PubMed ID: 20629031
[TBL] [Abstract][Full Text] [Related]
5. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
[TBL] [Abstract][Full Text] [Related]
6. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
[TBL] [Abstract][Full Text] [Related]
7. The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma.
Murthy SB; Patnana SV; Xiao L; Rohren E; Hofstetter WL; Swisher SG; Liao Z; Lee JH; Bhutani MS; Macapinlac HA; Wang X; Ajani JA
Oncology; 2010; 78(5-6):316-22. PubMed ID: 20699623
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy.
Suzuki A; Xiao L; Hayashi Y; Macapinlac HA; Welsh J; Lin SH; Lee JH; Bhutani MS; Maru DM; Hofstetter WL; Swisher SG; Ajani JA
Cancer; 2011 Nov; 117(21):4823-33. PubMed ID: 21456015
[TBL] [Abstract][Full Text] [Related]
9. The influence of (18)flourodeoxyglucose positron emission tomography on the management of gastroesophageal junction carcinoma.
Smith JW; Moreira J; Abood G; Aranha GV; Nagda S; Wagner RH; Shoup M
Am J Surg; 2009 Mar; 197(3):308-12. PubMed ID: 19245906
[TBL] [Abstract][Full Text] [Related]
10. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma.
Konski AA; Cheng JD; Goldberg M; Li T; Maurer A; Yu JQ; Haluszka O; Scott W; Meropol NJ; Cohen SJ; Freedman G; Weiner LM
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):358-63. PubMed ID: 17532577
[TBL] [Abstract][Full Text] [Related]
11. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.
Swisher SG; Erasmus J; Maish M; Correa AM; Macapinlac H; Ajani JA; Cox JD; Komaki RR; Hong D; Lee HK; Putnam JB; Rice DC; Smythe WR; Thai L; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
Cancer; 2004 Oct; 101(8):1776-85. PubMed ID: 15386332
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of maximum standardized uptake values from preoperative positron emission tomography in resectable adenocarcinoma of the esophagus treated by surgery alone.
Shenfine J; Barbour AP; Wong D; Thomas J; Martin I; Gotley DC; Smithers BM
Dis Esophagus; 2009; 22(8):668-75. PubMed ID: 19222534
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma.
Rizk NP; Tang L; Adusumilli PS; Bains MS; Akhurst TJ; Ilson D; Goodman K; Rusch VW
J Thorac Oncol; 2009 Jul; 4(7):875-9. PubMed ID: 19487968
[TBL] [Abstract][Full Text] [Related]
14. Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography.
Roedl JB; Harisinghani MG; Colen RR; Fischman AJ; Blake MA; Mathisen DJ; Mueller PR
Ann Thorac Surg; 2008 Oct; 86(4):1131-8. PubMed ID: 18805147
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Pretherapeutic Tumor-to-Blood Standardized Uptake Ratio in Patients with Esophageal Carcinoma.
Bütof R; Hofheinz F; Zöphel K; Stadelmann T; Schmollack J; Jentsch C; Löck S; Kotzerke J; Baumann M; van den Hoff J
J Nucl Med; 2015 Aug; 56(8):1150-6. PubMed ID: 26089549
[TBL] [Abstract][Full Text] [Related]
16. The clinical application of (18)F-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer.
Kato H; Nakajima M; Sohda M; Tanaka N; Inose T; Miyazaki T; Fukuchi M; Oriuchi N; Endo K; Kuwano H
Cancer; 2009 Jul; 115(14):3196-203. PubMed ID: 19472406
[TBL] [Abstract][Full Text] [Related]
17. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.
Lordick F; Ott K; Krause BJ; Weber WA; Becker K; Stein HJ; Lorenzen S; Schuster T; Wieder H; Herrmann K; Bredenkamp R; Höfler H; Fink U; Peschel C; Schwaiger M; Siewert JR
Lancet Oncol; 2007 Sep; 8(9):797-805. PubMed ID: 17693134
[TBL] [Abstract][Full Text] [Related]
18. Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma.
Ku GY; Kriplani A; Janjigian YY; Kelsen DP; Rusch VW; Bains M; Chou J; Capanu M; Wu AJ; Goodman KA; Ilson DH
Cancer; 2016 Jul; 122(13):2083-90. PubMed ID: 27152857
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer.
Levine EA; Farmer MR; Clark P; Mishra G; Ho C; Geisinger KR; Melin SA; Lovato J; Oaks T; Blackstock AW
Ann Surg; 2006 Apr; 243(4):472-8. PubMed ID: 16552197
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus.
Smithers BM; Couper GC; Thomas JM; Wong D; Gotley DC; Martin I; Harvey JA; Thomson DB; Walpole ET; Watts N; Burmeister BH
Dis Esophagus; 2008; 21(2):151-8. PubMed ID: 18269651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
